Charles J. Casamento Acquires 13,000 Shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD) Stock

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Director Charles J. Casamento purchased 13,000 shares of the stock in a transaction dated Monday, September 9th. The shares were bought at an average cost of $2.56 per share, for a total transaction of $33,280.00. Following the completion of the purchase, the director now owns 13,000 shares in the company, valued at $33,280. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.

Relmada Therapeutics Trading Down 5.5 %

Shares of NASDAQ RLMD opened at $3.09 on Friday. The stock has a market cap of $93.23 million, a price-to-earnings ratio of -0.99 and a beta of 0.50. Relmada Therapeutics, Inc. has a 52 week low of $1.88 and a 52 week high of $7.22. The company’s 50-day moving average price is $3.22 and its 200 day moving average price is $3.77.

Relmada Therapeutics (NASDAQ:RLMD) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.59) EPS for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.24. During the same quarter last year, the firm earned ($0.84) earnings per share. As a group, research analysts expect that Relmada Therapeutics, Inc. will post -2.39 earnings per share for the current year.

Analysts Set New Price Targets

Separately, The Goldman Sachs Group cut shares of Relmada Therapeutics from a “neutral” rating to a “sell” rating and lowered their price objective for the company from $3.00 to $2.00 in a research note on Wednesday, June 5th.

Institutional Investors Weigh In On Relmada Therapeutics

Large investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC purchased a new position in Relmada Therapeutics in the 1st quarter valued at about $53,000. State Board of Administration of Florida Retirement System purchased a new position in Relmada Therapeutics in the 1st quarter valued at about $70,000. American Century Companies Inc. lifted its holdings in Relmada Therapeutics by 14.6% in the 2nd quarter. American Century Companies Inc. now owns 31,618 shares of the company’s stock valued at $95,000 after purchasing an additional 4,027 shares in the last quarter. ADAR1 Capital Management LLC purchased a new position in Relmada Therapeutics in the 4th quarter valued at about $243,000. Finally, Renaissance Technologies LLC lifted its holdings in Relmada Therapeutics by 153.6% in the 2nd quarter. Renaissance Technologies LLC now owns 88,775 shares of the company’s stock valued at $266,000 after purchasing an additional 53,767 shares in the last quarter. 45.24% of the stock is owned by institutional investors and hedge funds.

Relmada Therapeutics Company Profile

Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder.